Nasdaq:KTTA
Pasithea Therapeutics Corp.
Pasithea Therapeutics is a biopharma developer of rare disease therapies with $6.9M in cash and a 2024 net loss of $13.9M driven by high R&D spending.
Key Metrics
Investment Thesis
Bull Case
Investors may view KTTA as a high-risk, high-reward opportunity given its focus on the lucrative rare disease market which often offers favorable regulatory pathways and pricing dynamics. The company has successfully secured enough funding to sustain operations with $6.9M in cash while building a pipeline that could yield blockbuster returns upon successful commercialization.
Bear Case
The stock carries extreme downside risk as the company is burning through its cash reserves at a rate of nearly $14M per year without any current revenue streams. Investors should be wary of potential equity dilution and the uncertainty surrounding the clinical success of their drug candidates in a highly competitive therapeutic landscape.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. (KTTA) is a biopharmaceutical company focused on developing novel therapies for rare diseases, specifically targeting conditions like Gaucher disease within the specialized pharmaceutical market. The company leverages its research and development pipeline to create differentiated treatments aimed at unmet medical needs in niche therapeutic areas. While currently generating no revenue from sales, the firm maintains significant cash reserves funded by financing activities to support its clinical programs and operational burn rate.
Analysis
Management Discussion
Management has allocated significant resources to research and development, with R&D expenses reaching $7.2M in 2024 while general and administrative costs totaled $7.1M, resulting in a consolidated net loss of $13.9M. Despite these losses, the company maintained a healthy current ratio by managing liabilities at $1.1M against current assets of $7.4M, though cash reserves have declined from $16.3M to $6.9M over the period. The negative cash flow from operations was partially offset by $4.5M in financing cash inflows, highlighting the capital-intensive nature of the business.
Industry Overview
The biotechnology sector for rare diseases is characterized by high barriers to entry, limited competition, and significant government incentives like orphan drug designation that can accelerate market approval. Companies in this space typically experience long development cycles with substantial upfront investment before realizing any commercial revenue from their product portfolios.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $486.6K | $0 | $0 |
| Cost of Revenue | $113.2K | $0 | $0 |
| Gross Profit | $373.4K | $0 | $0 |
| Operating Expenses | $15.2M | $16.0M | $14.2M |
| Operating Income | $-14.8M | $-16.0M | $-14.2M |
| R&D | $2.7M | $8.1M | $7.2M |
| G&A | $12.5M | $7.9M | $7.1M |
| Stock-Based Comp | $552.8K | $592.3K | $773.7K |
| Depreciation | $31.5K | $18.3K | $18.9K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $879.9K | $471.6K | $345.4K |
| Interest Expense | $102 | — | — |
| Pre-Tax Income | $-13.9M | $-15.5M | $-13.9M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-13.9M | $-15.5M | $-13.9M |
| Discontinued Ops | $0 | $-453.9K | $0 |
| Net Income | $-13.9M | $-16.0M | $-13.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-13.9M | $-16.0M | $-13.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $34.1M | $16.7M | $7.4M |
| Cash & Equivalents | $33.1M | $16.3M | $6.9M |
| Other Current Assets | $929.8K | $361.1K | $445.6K |
| Long-Term Assets | $11.1M | $9.4M | $8.7M |
| PP&E (Net) | $378.8K | $141.2K | $122.3K |
| Intangibles | $8.6M | $7.9M | $7.3M |
| Goodwill | $1.3M | $1.3M | $1.3M |
| Operating Leases | $874.5K | $79.3K | — |
| Other LT Assets | $0 | $0 | $0 |
| Total Assets | $45.2M | $26.1M | $16.1M |
| Current Liabilities | $1.9M | $2.6M | $1.1M |
| Current Leases | $263.3K | $81.7K | — |
| Other Current Liab | $1.6M | $2.6M | — |
| Long-Term Liabilities | $804.2K | $84.4K | $162.2K |
| LT Operating Leases | $663.6K | — | — |
| Other LT Liab | $140.6K | — | — |
| Total Liabilities | $2.7M | $2.7M | $1.3M |
| Shareholders' Equity | $42.5M | $23.4M | $14.8M |
| Paid-In Capital | $61.8M | $58.7M | $64.4M |
| Retained Earnings | $-19.4M | $-35.3M | $-49.6M |
| AOCI | $-661 | $-4.7K | $-7.2K |
| Total L&E | $45.2M | $26.1M | $16.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-13.9M | $-16.0M | $-13.9M |
| Non-Cash Adjustments | $-575.0K | $2.0M | $1.3M |
| Working Capital Changes | $-50.5K | $564.7K | $-1.4M |
| Cash from Operations | $-14.6M | $-13.4M | $-13.9M |
| Capital Expenditures | $374.9K | $34.3K | — |
| Cash from Investing | $-2.1M | $399.0K | $0 |
| Share Buybacks | — | $3.7M | — |
| Cash from Financing | $-3.2M | $-3.7M | $4.5M |
| FX Effect | $9.9K | $-4.0K | $-2.5K |
| Net Change in Cash | $-19.8M | $-16.8M | $-9.4M |
| Beginning Cash | $53.0M | $33.1M | $16.3M |
| Ending Cash | $33.1M | $16.3M | $6.9M |
Frequently Asked Questions
How does Pasithea Therapeutics Corp. make money?
The company operates primarily through its drug development segment, focusing on proprietary therapeutics for rare diseases such as Gaucher disease, with all current financial activity directed toward research and administrative functions rather than commercial sales.
What are the main risks for KTTA?
The company faces severe financial risk due to its negative operating cash flow of $13.9M and reliance on external financing to cover burn rates. There is a substantial risk of dilution if additional capital raises are required before achieving commercial milestones, alongside the inherent clinical trial failure risks common in biotechnology.
What is KTTA's competitive advantage?
Pasithea possesses deep scientific expertise in rare disease mechanisms, a focused pipeline of differentiated assets with potential for high pricing power, and access to specialized grant funding or partnership opportunities common in the orphan drug space.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.